Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology.
Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Macaluso FS, et al. Among authors: papi c. Dig Liver Dis. 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17. Dig Liver Dis. 2022. PMID: 35184989 Free article.
Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto.
Riegler G, D'Incà R, Sturniolo GC, Corrao G, Del Vecchio Blanco C, Di Leo V, Carratù R, Ingrosso M, Pelli MA, Morini S, Valpiani D, Cantarini D, Usai P, Papi C, Caprilli R. Riegler G, et al. Among authors: papi c. Scand J Gastroenterol. 1998 Jan;33(1):93-8. doi: 10.1080/00365529850166275. Scand J Gastroenterol. 1998. PMID: 9489915
Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.
Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Cammà C, Corrao G, Latella G. Caprilli R, et al. Among authors: papi c. Aliment Pharmacol Ther. 2003 Feb 15;17(4):517-23. doi: 10.1046/j.1365-2036.2003.01462.x. Aliment Pharmacol Ther. 2003. PMID: 12622760 Free article. Clinical Trial.
Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study.
Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, D'Incà R, Gionchetti P, Papi C, Riegler G, Vecchi M, Andriulli A; Italian Group for Inflammatory Bowel Disease. Annese V, et al. Among authors: papi c. Dig Liver Dis. 2004 Feb;36(2):121-4. doi: 10.1016/j.dld.2003.10.010. Dig Liver Dis. 2004. PMID: 15002819
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M; Italian Multicentric Study Group on Infliximab. Orlando A, et al. Among authors: papi c. Dig Liver Dis. 2005 Aug;37(8):577-83. doi: 10.1016/j.dld.2005.01.019. Dig Liver Dis. 2005. PMID: 15886081 Clinical Trial.
182 results